Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00807235 · ClinicalTrials.gov registry record · Phase 2
Feasibility Study of Aerosolized Surfaxin in the Prevention of Respiratory Distress Syndrome (RDS) in Premature Infants
A Phase 2 study, sponsored by Windtree Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 17
- Enrollment target
NCT00807235 is a Phase 2 study that was terminated before completion, run by Windtree Therapeutics. The registered enrollment target is 17 participants.
The verdict
NCT00807235, a Phase 2 study, was terminated before completion, sponsored by Windtree Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 17 participants
- Enrollment target
Study Summary
To evaluate the feasibility, safety and tolerability of aerosolized lucinactant delivered by nasal continuous positive airway pressure (nCPAP) for the prevention of respiratory distress syndrome (RDS) in premature infants.
Interventions
- DRUG Aerosolized lucinactant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2005-01 |
| Est. Completion | 2005-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00807235
The ClinicalTrials.gov registry entry for NCT00807235 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Windtree Therapeutics, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Aerosolized lucinactant is the first listed.
NCT00807235 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00807235 about?
NCT00807235 is a clinical study titled "Feasibility Study of Aerosolized Surfaxin in the Prevention of Respiratory Distress Syndrome (RDS) in Premature Infants". To evaluate the feasibility, safety and tolerability of aerosolized lucinactant delivered by nasal continuous positive airway pressure (nCPAP) for the prevention of respiratory distress syndrome (RDS) in premature infants.
What is the current status of trial NCT00807235?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2005-01. Estimated completion is 2005-09.
What interventions are being tested in trial NCT00807235?
The interventions under investigation include: Aerosolized lucinactant (DRUG).
Who is sponsoring clinical trial NCT00807235?
This trial is sponsored by Windtree Therapeutics, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.